-
Board Certification
American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
4.9 /5( out of 56 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.February 23, 2024HUNTSMAN CANCER CENTERHannah is intelligently disabled and I liked how Dr. Chalmers included both Hannah and I l, her mother, when speaking about her condition and treatment.
February 13, 2024HUNTSMAN CANCER CENTERI didn't get to talk to Dr. Chalmers until after she got out of her meeting but she confirmed everything that Melissa Shepherd and I had talked about earlier.
February 13, 2024HUNTSMAN CANCER CENTERWithin moments of meeting Dr. Chalmers and her very capable team, I was sure that my unknown cancer future ahead would be an improved and more hopeful one because of their professional and dedicated care.
February 12, 2024HUNTSMAN CANCER CENTERDr. Chalmers always takes the necessary time to answer my questions.
February 01, 2024HUNTSMAN CANCER CENTERSuperb, knowledgeable Oncologist with empathetic, kind, attentive, responsive manner. She keeps me alive, and, for the most part, having a good quality of life.
January 27, 2024HUNTSMAN CANCER CENTERI love Dr. Chalmers. She really does a great job in trying to make sure I am well informed about concerns and treatment options.
December 21, 2023HUNTSMAN CANCER CENTERShe is absolutely amazing in her care and making sure you understand and like you are family
November 17, 2023HUNTSMAN CANCER CENTERVery caring and professional!!!
November 14, 2023HUNTSMAN CANCER CENTERAnna Chalmers has been guiding me through my struggles with leomyosarcoma for 16 years and has kept me up to date on what the CT and MRI scans have shown about my insides. She is very pleasant and knowledgeable and is a joy to work with.
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Oncology
Board Certification American Board of Internal MedicineAmerican Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Fellowship Hematology and Medical Oncology - Rush University Medical Center Fellow Internal Medicine - Rush University Medical Center Resident Professional Medical Medicine - Drexel University College of Medicine M.D. Dartmouth College B.A. Selected Publications
Journal Article
- Puri S, Malani R, Chalmers A, Kerrigan K, Patel SB, Monynahan K, Cannon L, Blouw B, Akerley W (2023). Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide(TM). Neurooncol Adv, 6(1), vdad150. (Read full article)
- Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, 16(4), e313-e323. (Read full article)
- Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421. (Read full article)
- Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972. (Read full article)
Editorial
- Chalmers AW, Patel SB, Akerley W (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis, 10(3), 1198-1200. (Read full article)
Letter
- Chalmers A, Akerley W (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. [Letter to the editor]. J Clin Oncol, 35(20), 2340. (Read full article)
-
News & Podcasts
Huntsman Cancer Institute News